Business Wire

CA-FORESCOUT-TECH

6.6.2022 15:02:12 CEST | Business Wire | Press release

Share
Forescout Announces Intent to Acquire Cysiv to Deliver Data-Powered Threat Detection and Response

Forescout Technologies, Inc. , the global leader in automated cybersecurity, today announced that it has signed a definitive agreement to acquire Cysiv , a cybersecurity innovator that uses its cloud platform to improve detection and response of true threats. With this acquisition, Forescout will leverage Cysiv’s threat detection engine to analyze a wealth of asset and network communications data automatically collected by Forescout’s platform. This comprehensive data across IT, IoT, OT and IoMT devices, as well as other essential data sources, enables better true threat detection and response so customers can operate more securely and efficiently. Upon the close of the acquisition, Cysiv will join Forescout.

“Organizations need to be able to reduce the billions of data points on their networks to a handful of actionable true threats – automatically. Together with Cysiv, Forescout will provide customers with the most powerful platform for automated cybersecurity across their digital terrains,” said Wael Mohamed, CEO of Forescout. “Upon close, the acquisition will help our customers leverage actionable threat intelligence from comprehensive data collected by Forescout and analyzed by Cysiv. We will receive far more than just great technology in this acquisition. The Cysiv team is exceptional, and our two organizations are highly complementary.”

Today, organizations are faced with the immense pressure to secure their networks. CIOs and CISOs have experienced rapid growth in the volume and diversity of managed and unmanaged devices, including IoT devices, that has given rise to increased risks and cybersecurity threats, coinciding with a drop in available cybersecurity resources. With the rapid adoption of cloud, and a cloud-first mindset that’s been accelerated by the work-from-anywhere shift of the past two years, enterprises are particularly concerned with managing threats to these fluid threat environments. This has resulted in organizations not being able to effectively manage the detection, investigation, escalation and response of true threats, particularly as the threat landscape and unmanaged device landscape have become more complex.

Existing solutions for threat detection and response, such as EDR, require the use of agents on managed devices. This means that organizations dependent on an agent-based approach for threat detection and response are not able to look for threats coming from the majority of their connected devices, particularly critical assets like IoT, IoMT and OT.

For over a decade, Forescout’s ability to deeply integrate into the fabric of customers’ networks has enabled it to collect real-time data for all connected assets and users, together with the communications among those assets and users. Customers have been asking Forescout to leverage this comprehensive data to provide greater insight into threats for all types of assets and to enable faster, more automated response and remediation.

“We have always been on a mission to provide better threat detection and faster response,” said Partha Panda, CEO and co-founder of Cysiv. “After successfully partnering together for the last year, we are thrilled to join Forescout as we continue on the next stage of our journey. The combination of Forescout and Cysiv will provide organizations with best-in-class threat detection together with automated incident prioritization and automated response.”

The acquisition is expected to close in July, 2022, subject to the satisfaction of closing conditions and receipt of applicable regulatory approvals and comes on the heels of its acquisition of CyberMDX which further strengthens Forescout’s industry-leading IT, IoT and OT device coverage with IoMT expertise.

About Forescout

Forescout Technologies, Inc. delivers cybersecurity automation across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types. The Forescout Continuum Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com

Managing cyber risk, together.

© 2022 Forescout Technologies, Inc. All rights reserved. Forescout Technologies, Inc. is a Delaware corporation. A list of our trademarks and patents can be found at https://www.forescout.com/company/legal/intellectual-property-patents-trademarks . Other brands, products, or service names may be trademarks or service marks of their respective owners.

About Cysiv

Cysiv security operations center (SOC)-as-a-service provides enterprises with better detection and faster response of true threats. We do this by uniquely combining our cloud-native next generation SIEM, with a data-centric approach and a team of experts that operate as a seamless extension of your SOC. All of this is delivered as a subscription-based service, with predictable and flexible pricing, that can be operational in weeks. Cysiv’s modern approach to threat detection and response helps reduce risk, ensure compliance, and improve the efficiency, effectiveness and maturity of your security operations. To learn more, visit www.cysiv.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release

~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye